UroGen PharmaFRA:UR8 -3.09%61 Days Payable is 321.72 as of Mar. 2026, which is 10% below its 10-year median of 358.49. GuruFocus rates FRA:UR8 with a GF Score™ of 61/100 and a GF Value™ of €17.51 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 699 Biotechnology companies, UroGen Pharma ranks better than 73.53% on this metric.
The historical rank and industry rank for UroGen Pharma's Days Payable or its related term are showing as below:
FRA:UR8'
s Days Payable Range Over the Past 10 Years
Min: 234.75 Med: 358.49 Max: 23516.43
Current: 346.95
During the past 11 years, UroGen Pharma's highest Days Payable was 23516.43. The lowest was 234.75. And the median was 358.49.
FRA:UR8's Days Payable is ranked better than 73.53% of 699
companies
in the Biotechnology industry
Industry Median: 112.84
vs FRA:UR8: 346.95
UroGen Pharma's Days Payable
declined
from Mar. 2025 (506.28) to Mar. 2026 (321.72).
It may suggest that UroGen Pharmaaccelerated paying its suppliers.
UroGen Pharma Days Payable Related Terms
UroGen Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UR8 vs SEPN, FTRE, MLTX: Days Payable Comparison
For the Biotechnology subindustry, UroGen Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
UroGen Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (FRA:UR8) has a Days Payable of 321.72 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on UroGen Pharma and its competitors. This is 10% below median its historical median of 358.49. Over the past decade, UroGen Pharma's Days Payable has ranged from 234.75 to 23,516.43. According to the industry distribution chart, UroGen Pharma ranks #185 out of 699 companies in the Biotechnology industry, placing it in the top 26.5%.
Is UroGen Pharma's Days Payable too high?
UroGen Pharma's current Days Payable of 321.72 is 10% below median its 10-year median of 358.49. Over the past 10 years, this metric has ranged from a low of 234.75 to a high of 23,516.43. The Biotechnology industry median Days Payable is 112.84. UroGen Pharma's value of 321.72 is 185.1% above this industry median. Based on the distribution chart, UroGen Pharma ranks #185 out of 699 companies in the Biotechnology industry, which is above the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Days Payable compare to SEPN and FTRE?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #185 out of 699 companies for Days Payable. This puts UroGen Pharma in the upper half of its industry. The industry median Days Payable is 112.84. UroGen Pharma's value of 321.72 is 185.1% above this benchmark. Historically, UroGen Pharma's own Days Payable has ranged from 234.75 to 23,516.43 over the past decade. While the company's 10-year median is 358.49 vs. the industry median of 112.84, UroGen Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current Days Payable of 321.72 is 185.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on UroGen Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Days Payable is 321.72, which is 10% below median its own 10-year median of 358.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.51, compared to a current price of €31.98 — trading 82.6% above its estimated fair value. The current Days Payable is 321.72, which is 10% below median its 10-year median of 358.49 and 185.1% above the Biotechnology industry median of 112.84. UroGen Pharma's overall GF Score™ is 61/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Days Payable is 321.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €31.98 is trading 82.6% above its estimated GF Value™ of €17.51.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
Days Payable: 321.72 (10% below median its 10-year median of 358.49)
GF Value™: €17.51 vs. price of €31.98 (82.6% above fair value)
Industry Position: 185.1% above the Biotechnology median (#185 of 699)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
61GF Score
Get the complete analysis for FRA:UR8
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
